MDT — Medtronic plc

Medtronic (MDT) Q4 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $9.8 billion, up 9.9% reported and 6.6% organically.
• Full Year Revenue: $36.4 billion, up 8.4% reported and 5.8% organically, marking the strongest performance in a decade.
• Adjusted EPS: Q4 at $1.55 and FY '26 at $5.53, both exceeding expectations.
• Free Cash Flow: $5.4 billion for FY '26, the highest since 2022.
• Adjusted Gross Margin: 65.4%, a 30 basis point increase year-over-year.

2. Strategic Updates and Business Highlights

• Cardiac Ablation Solutions (CAS): Achieved 78% worldwide growth, with a 145% increase in PFA. The U.S. installed base grew by 40% sequentially.
• Symplicity Spyral: Annualizing at $100 million, with significant clinical outcomes reinforcing its effectiveness in treating hypertension.
• Hugo Surgical Robotics: Procedure volume growth is 2x to 3x the market rate, with positive early feedback from urology launches.
• Altaviva: Strong early demand and physician training leading to a 3x increase in active implanters.
• M&A Activity: Completed the MiniMed IPO and made several acquisitions to enhance growth in neurovascular and pain management sectors.

3. Forward Guidance and Outlook

• FY '27 Organic Revenue Growth: Expected between 6.75% to 7.25%, with approximately 11.5% to 12% growth in Q1.
• EPS Guidance: Projected between $5.90 to $6.00.
• Margin Expectations: Operating margin anticipated to improve by 60 basis points, with gross margin slightly decreasing due to tariffs but expected to stabilize in the second half of FY '27.

4. Challenges and Points of Concern

• TAVR Business: Experienced a slowdown in growth, particularly in the U.S., attributed to low-risk data affecting market dynamics.
• Tariffs: Ongoing tariff impacts are expected to constrain gross margins, with a total estimated impact of $250 million for FY '27.
• Competitive Pressures: Concerns about market share in TAVR and the need for innovation to maintain growth amidst established competitors.

5. Notable Q&A Insights

• CAS Growth: Management emphasized that CAS will continue to contribute significantly to growth, with expectations of maintaining market leadership.
• TAVR Stability: The TAVR business has stabilized after recent challenges, with investments planned to enhance competitiveness.
• MiniMed Separation Rationale: The decision to separate MiniMed is based on capital allocation priorities, not a lack of confidence in its growth potential.
• China Market: Despite challenges, China remains a growth market with strong profitability, and the team is navigating pricing pressures effectively.

Overall, Medtronic reported strong financial results for Q4 2026, driven by robust performance in key segments, while also outlining a positive outlook for FY '27 amidst some challenges in specific areas like TAVR and tariff impacts.